Recipharm AB (publ) (OM:RECI B) agreed to acquire remaining 26% stake in Nitin Lifesciences Limited from Sobti family for INR 2.6 billion on January 2, 2018. The consideration is arrived on a cash and debt free basis whereof INR 600 million will be paid in newly issued Recipharm shares (RECI-B). As per the agreement, the consideration will be paid in two steps; the cash part on January 2, 2018 and the part paid in Recipharm shares later during the first half of 2018. The executive management in India will remain unchanged. The deal is expected to be accretive to earnings per share of Recipharm AB.